Interplay between B7–H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma

Giulia Cattaneo,Marco Ventin,Shahrzad Arya,Filippos Kontos,Theodoros Michelakos,Yurie Sekigami,Lei Cai,Vincenzo Villani,Francesco Sabbatino,Francine Chen,Ananthan Sadagopan,Vikram Deshpande,Paul A Moore,David T Ting,Nabeel Bardeesy,Xinhui Wang,Soldano Ferrone,Cristina R Ferrone,Paul A. Moore,David T. Ting,Cristina R. Ferrone

DOI: https://doi.org/10.1016/j.canlet.2024.216713

IF: 9.756

2024-04-01

Cancer Letters

Abstract:Human leukocyte antigen (HLA) class I defects are associated with cancer progression. However, their prognostic significance is controversial and may be modulated by immune checkpoints. Here, we investigated whether the checkpoint B7-H3 modulates the relationship between HLA class I and pancreatic ductal adenocarcinoma (PDAC) prognosis. PDAC tumors were analyzed for the expression of B7-H3, HLA class I, HLA class II molecules, and for the presence of tumor-infiltrating immune cells. We observed defective HLA class I and HLA class II expressions in 75% and 59% of PDAC samples, respectively. HLA class I and B7-H3 expression were positively related at mRNA and protein level, potentially because of shared regulation by RELA, a sub-unit of NF-kB. High B7-H3 expression and low CD8⁺ T cell density were indicators of poor survival, while HLA class I was not. Defective HLA class I expression was associated with unfavorable survival only in patients with low B7-H3 expression. Favorable survival was observed only when HLA class I expression was high and B7-H3 expression low. Our results provide the rationale for targeting B7-H3 in patients with PDAC tumors displaying high HLA class I levels.

oncology